Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T21:39:02.126Z.
Calculation as of: 2026-10-06T21:39:02.126Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: cafac005872c57a3e4a0b6cd3f460881363b31539507c7b963fc5044b4159481
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-17.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
EV/SALES RATIO AVG TTM
N/A
EV/SALES RATIO AVG 3Y
N/A
EV/SALES RATIO AVG 5Y
N/A
EV/SALES RATIO AVG 10Y
N/A
EV/SALES RATIO AVG 15Y
N/A
EV/SALES RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$545796.00
EV/Sales Ratio
0.95x
TTM Avg
22.73x
3Y Avg
233.34x
5Y Avg
409.95x
Market Cap
$378849.00
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$667469.00
EV/Sales Ratio
N/A
TTM Avg
18336.38x
3Y Avg
32990.15x
5Y Avg
90979.77x
Market Cap
$824550.00
EV/Sales Ratio
N/A
TTM Avg
78.84x
3Y Avg
47.25x
5Y Avg
902.93x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| VivoSim Labs, Inc. (VIVS) | $518606.00 | N/A | N/A | N/A | N/A |
| HCW Biologics Inc. (HCWB)vs › | $545796.00 | 0.95x | 22.73x | 233.34x | 409.95x |
| XORTX Therapeutics Inc. (XRTX)vs › | $481786.00 | N/A | N/A | N/A | N/A |
| Niki BioSolutions, Inc. (NIKI)vs › | $403887.00 | N/A | N/A | N/A | N/A |
| Virax Biolabs Group Limited (VRAX)vs › | $378849.00 | N/A | N/A | N/A | N/A |
| China SXT Pharmaceuticals, Inc. (SXTC)vs › | $667469.00 | N/A | 18336.38x | 32990.15x | 90979.77x |
| CDT Equity Inc. (CDT)vs › | $716854.00 | 0.67x | 1.27x | 1.27x | 1.27x |
| SciSparc Ltd. (SPRC)vs › | $250443.00 | N/A | N/A | N/A | N/A |
| Decoy Therapeutics Inc. (DCOY)vs › | $824550.00 | N/A | 78.84x | 47.25x | 902.93x |
| Ridgetech, Inc. (RDGT)vs › | $835994.00 | N/A | 0.20x | 0.19x | 0.16x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/SALES RATIO |
|---|---|
| 2026-09-17 | 0.03x |
| 2026-09-16 | 0.17x |
| 2026-09-15 | 0.66x |
| 2026-09-14 | 1.06x |
| 2026-09-11 | 1.15x |
| 2026-09-10 | 1.94x |
| 2026-09-09 | 0.78x |
| 2026-09-08 | 1.09x |
| 2026-09-04 | 0.93x |
| 2026-09-03 | 0.96x |
| 2026-09-02 | 1.00x |
| 2026-09-01 | 0.95x |
| 2026-08-31 | 1.54x |
| 2026-08-28 | 1.26x |
| 2026-08-27 | 1.62x |
| 2026-08-26 | 1.52x |
| 2026-08-25 | 1.55x |
| 2026-08-24 | 1.57x |
| 2026-08-21 | 1.29x |
| 2026-08-20 | 0.89x |
| 2026-08-19 | 0.88x |
| 2026-08-18 | 0.94x |
| 2026-08-17 | 2.79x |
| 2026-08-14 | 3.00x |
| 2026-08-13 | 3.26x |
| 2026-02-05 | 0.56x |
| 2026-02-03 | 2.21x |
| 2026-01-30 | 3.96x |
